Recombinant MAGE-A3 vaccination with the AS15 immunostimulant, which contains CpG, a TLR9 stimulant, was assessed in patients with melanoma and non-small cell lung cancer but did not produce a survival benefit [51, 52]. This evidence concerns the gene TLR9 and non-small cell lung carcinoma.